DESTINY-Gastric03: T-DXd, fluoropyrimidine and pembrolizumab in HER2+ GEJA
Yelena Janjigian, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses Part 2 of the DESTINY-Gastric03 trial (NCT04379596), which evaluated trastuzumab deruxtecan (T-DXd) with capecitabine and pembrolizumab as first-line therapy for HER2+ esophageal, gastric, or gastroesophageal junction adenocarcinoma (GEJA). The combination demonstrated promising antitumor activity, but combination of full-dose T-DXd with capecitabine and pembrolizumab had higher grade adverse events. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
